(Q33926422)

30 July 2017

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents (English)

1 reference

30 July 2017

Meanwell NA

1

1 reference

PubMed ID

10825730

30 July 2017

Krystal M

series ordinal

2

1 reference

30 July 2017

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

5

1 reference

30 July 2017

6

1 reference

30 July 2017

241-252

1 reference

Recovery of cytopathogenic agent from chimpanzees with coryza

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus (RSV) disease and prospects for its control

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Animal models of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Treatment and prevention options for respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Epidemiology of acute lower respiratory disease in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

National surveillance for respiratory syncytial virus, United States, 1985-1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Modes of transmission of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory Syncytial Virus Infections within Families

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Neonatal respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Mechanisms of virus induced exacerbations of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Asthma and respiratory syncytial virus infection in infancy: is there a link?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory viruses in acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Role of Viruses in Middle-ear Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Prevalence of Various Respiratory Viruses in the Middle Ear during Acute Otitis Media

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus infection in immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus pneumonia in a cardiac transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus infection in older persons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus or influenza?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Prospects for a respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Protection against respiratory syncytial virus infection by DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

A novel and effective intranasal immunization strategy for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

The therapeutic potential of monoclonal antibodies against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Approaches to antiviral chemotherapy for acute respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Biochemistry and clinical applications of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Effects of ribavirin on respiratory syncytial virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

In vivo inhibition of respiratory syncytial virus by ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Polyoxometalates in Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Novel and specific respiratory syncytial virus inhibitors that target virus fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Aromatic amidines. Comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Design of potent selective zinc-mediated serine protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901500-2

7 January 2021

10.1016/S1359-6446(00)01500-2

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10825730